Several times a month, Michael Sherman, MD, gets a call from someone curious about his deal-making. Sherman is not a venture capitalist or head of technology transfer at a university, though. He is chief medical officer at Harvard Pilgrim Health Care Inc., which is the second largest health insurer in New England. But his willingness to embrace a controversial approach in the US toward negotiating with drugmakers has placed him at the center of a growing debate over the value of prescription medicines.
Over the past two years, he has inked half a dozen outcomes-based contracts with drug companies, making Harvard Pilgrim something...



![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)


